8-K filed Jul 17, 2026 at 17:01 ET
Karyopharm Therapeutics implemented a 2026 Leadership Cash Retention Program providing lump-sum cash awards totaling $3.715 million to its CEO, CFO, and two other named executive officers. The program replaces the 2026 Annual Bonus Plan and is designed to retain key personnel through an upcoming catalyst period, with awards subject to clawback if employment terminates before 12 months (or 30 days post-change-of-control). This is a routine compensatory arrangement with no departure or appointment of officers, neutral for the stock.